Aug. 12, 2022 |
|
Feb. 12, 2023 |
|
jRCT2031220266 |
An Open-Label, Long-Term Phase III Study of STN1012600 Ophthalmic Solution Alone and in Combination with Timolol Ophthalmic Solution, in Subjects with Open Angle Glaucoma or Ocular Hypertension |
|
A long term study of STN1012600 in subjects with open angle glaucoma or ocular hypertension |
Koji Oka |
||
Santen pharmaceutical co.,ltd |
||
4-20 Ofuka-cho, Kita-ku, Osaka, Japan |
||
+81-6-4802-9341 |
||
clinical@santen.co.jp |
||
Koji Oka |
||
Santen pharmaceutical co.,ltd |
||
4-20 Ofuka-cho, Kita-ku, Osaka, Japan |
||
+81-6-4802-9341 |
||
clinical@santen.co.jp |
Recruiting |
Aug. 08, 2022 |
||
Aug. 24, 2022 | ||
138 | ||
Interventional |
||
randomized controlled trial |
||
open(masking not used) |
||
active control |
||
parallel assignment |
||
treatment purpose |
||
18 years of age or older. |
||
Presence of any active severe external ocular disease, inflammation, or infection of the eye and/or eyelids in either eye. |
||
18age old over | ||
No limit | ||
Both |
||
open angle glaucoma (OAG) or ocular hypertension (OHT) |
||
Group 1: 1 drop STN1012600 0.002% once daily |
||
Adverse Events |
||
Santen pharmaceutical co.,ltd |
ShinAkasaka Clinic IRB | |
5-5-1, Roppongi, Minato-ku, Tokyo, Tokyo | |
+81-3-5770-1250 |
|
irb-shinakasaka@sin-akasaka.com | |
Approval | |
No |
|
現在、取得中(取得後に入力) | |
ClinicalTrials.gov |
none |